PRODUCT ADMINISTERED AT INAPPROPRIATE SITE

This adverse event was reported 18346 times

These drugs are most commonly taken by patients reporting PRODUCT ADMINISTERED AT INAPPROPRIATE SITE:

# Drug Count
0 DICLOFENAC SODIUM 7114
1 TIRZEPATIDE 1332
2 DICLOFENAC 802
3 MINOXIDIL 769
4 DICLOFENAC SODIUM 1% 733
5 DICLOFENAC SODIUM TOPICAL 733
6 DICLOFENAC SODIUM TOPICAL GEL, 1% 733
7 MINOXIDIL FOAM 5% (WOMENS) 674
8 DUPILUMAB 617
9 DULAGLUTIDE 517
See all common drugs associated with PRODUCT ADMINISTERED AT INAPPROPRIATE SITE

PRODUCT ADMINISTERED AT INAPPROPRIATE SITE is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 APPLE CIDER VINEGAR ANTI-DANDRUFF LEAVE-IN 1 1.0000
1 CLOTRIMAZOLE TOPICAL SOLUTION USP, 1% 3 0.1875
2 ALUMINUM CHLOROHYDRATE 5 0.1111
3 CALCIPOTRIENE CREAM, 0.005% 10 0.0971
4 ATEZOLIZUMAB AND HYALURONIDASE-TQJS 2 0.0833
5 MENADIONE 10 0.0719
6 ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 2 0.0556
7 ARIPIPRAZOLE LAUROXIL 219 0.0475
8 DICLOFENAC SODIUM 7114 0.0469
9 TRASTUZUMAB AND HYALURONIDASE-OYSK 4 0.0374
See all drugs enriched for association with PRODUCT ADMINISTERED AT INAPPROPRIATE SITE

PRODUCT ADMINISTERED AT INAPPROPRIATE SITE is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-5 Antagonist [EPC] 26 0.0378
1 PCSK9 Inhibitor [EPC] 658 0.0256
2 Endoglycosidase [EPC] 40 0.0216
3 Thyroid Stimulating Hormone [EPC] 21 0.0202
4 Oxaborole Antifungal [EPC] 1 0.0143
5 Cytolytic Agent [EPC] 27 0.0116
6 Pyrethroid [EPC] 19 0.0108
7 Parathyroid Hormone-Related Peptide Analog [EPC] 321 0.0103
8 Arteriolar Vasodilator [EPC] 785 0.0100
9 5-alpha Reductase Inhibitor [EPC] 702 0.0068
See all drug classes enriched for association with PRODUCT ADMINISTERED AT INAPPROPRIATE SITE